These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18361926)

  • 1. Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model.
    Ramírez PJ; Vickers SM; Ono HA; Davydova J; Takayama K; Thompson TC; Curiel DT; Bland KI; Yamamoto M
    Am J Surg; 2008 Apr; 195(4):481-90. PubMed ID: 18361926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer.
    Yamamoto M; Davydova J; Wang M; Siegal GP; Krasnykh V; Vickers SM; Curiel DT
    Gastroenterology; 2003 Oct; 125(4):1203-18. PubMed ID: 14517802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment.
    Davydova J; Le LP; Gavrikova T; Wang M; Krasnykh V; Yamamoto M
    Cancer Res; 2004 Jun; 64(12):4319-27. PubMed ID: 15205347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy.
    Armstrong L; Arrington A; Han J; Gavrikova T; Brown E; Yamamoto M; Vickers SM; Davydova J
    Am J Surg; 2012 Nov; 204(5):741-50. PubMed ID: 22748294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus.
    Kaliberov SA; Kaliberova LN; Buchsbaum DJ; Curiel DT
    Cancer Gene Ther; 2014 Jul; 21(7):264-74. PubMed ID: 24903014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenoviral therapy in gallbladder carcinoma.
    Tekant Y; Davydova J; Ramirez PJ; Curiel DT; Vickers SM; Yamamoto M
    Surgery; 2005 May; 137(5):527-35. PubMed ID: 15855925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
    Onimaru M; Ohuchida K; Nagai E; Mizumoto K; Egami T; Cui L; Sato N; Uchino J; Takayama K; Hashizume M; Tanaka M
    Cancer Lett; 2010 Aug; 294(2):178-86. PubMed ID: 20163915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
    Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5/35 fiber-modified conditionally replicative adenovirus armed with p53 shows increased tumor-suppressing capacity to breast cancer cells.
    He X; Liu J; Yang C; Su C; Zhou C; Zhang Q; Li L; Wu H; Liu X; Wu M; Qian Q
    Hum Gene Ther; 2011 Mar; 22(3):283-92. PubMed ID: 20846024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.
    Zhu ZB; Lu B; Park M; Makhija SK; Numnum TM; Kendrick JE; Wang M; Tsuruta Y; Fisher P; Alvarez RD; Zhou F; Siegal GP; Wu H; Curiel DT
    Int J Oncol; 2008 Jun; 32(6):1179-88. PubMed ID: 18497979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditionally replicative adenoviral vectors for imaging the effect of chemotherapy on pancreatic cancer cells.
    Kimura J; Ono HA; Kosaka T; Nagashima Y; Hirai S; Ohno S; Aoki K; Julia D; Yamamoto M; Kunisaki C; Endo I
    Cancer Sci; 2013 Aug; 104(8):1083-90. PubMed ID: 23679574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
    Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
    Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.
    Ranki T; Kanerva A; Ristimäki A; Hakkarainen T; Särkioja M; Kangasniemi L; Raki M; Laakkonen P; Goodison S; Hemminki A
    Gene Ther; 2007 Jan; 14(1):58-67. PubMed ID: 16900223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
    González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
    J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells.
    Onimaru M; Ohuchida K; Mizumoto K; Nagai E; Cui L; Toma H; Takayama K; Matsumoto K; Hashizume M; Tanaka M
    Cancer Sci; 2010 Mar; 101(3):735-42. PubMed ID: 20059477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
    He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
    Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectivity-Enhanced, Conditionally Replicative Adenovirus for COX-2-Expressing Castration-Resistant Prostate Cancer.
    Gavrikova T; Nakamura N; Davydova J; Antonarakis ES; Yamamoto M
    Viruses; 2023 Mar; 15(4):. PubMed ID: 37112881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.